COVID-19 mRNA vaccine effectiveness (second and first booster dose) against hospitalisation and death during Omicron BA.5 circulation: cohort study based on electronic health records, Portugal, May to July 2022.
Euro Surveill
; 27(37)2022 09.
Article
en En
| MEDLINE
| ID: mdl-36111555
ABSTRACT
We measured vaccine effectiveness (VE) against COVID-19-related severe outcomes in elderly people in Portugal between May and July 2022. In ≥â¯80 year-olds, the second booster dose VE was 81% (95%â¯CI 75-85) and 82% (95%â¯CI 77-85), respectively, against COVID-19-related hospitalisation and death. The first booster dose VE was 63% (95%â¯CI 55-70) in ≥ 80 year-olds and 74% (95%â¯CI 66-80) in 60-79 year-olds against hospitalisation, and 63% (95%â¯CIâ¯57-69) and 65% (95%â¯CI 54-74) against death.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Contexto en salud:
1_ASSA2030
/
2_ODS3
/
4_TD
/
6_ODS3_enfermedades_notrasmisibles
Problema de salud:
1_doencas_nao_transmissiveis
/
1_sistemas_informacao_saude
/
2_muertes_prematuras_enfermedades_notrasmisibles
/
4_covid_19
/
4_pneumonia
/
6_other_respiratory_diseases
Asunto principal:
Vacunas contra la COVID-19
/
COVID-19
Tipo de estudio:
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Risk_factors_studies
Límite:
Aged
/
Humans
País/Región como asunto:
Europa
Idioma:
En
Revista:
Euro Surveill
Asunto de la revista:
DOENCAS TRANSMISSIVEIS
Año:
2022
Tipo del documento:
Article
País de afiliación:
Portugal
